Background: Primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) is associated with higher chemotherapy relative dose intensity, which may lead to improved outcomes; however, the association between G-CSF primary prophylaxis and overall survival (OS) is not well characterized. This study assessed the effect of G-CSF primary prophylaxis on patient outcomes in randomized, controlled, registrational clinical trials of filgrastim and pegfilgrastim.
introduction
Severe neutropenia (SN) and febrile neutropenia (FN) are doselimiting toxicities of myelosuppressive chemotherapy that may lead to chemotherapy dose delays or dose reductions [1] [2] [3] . Prophylactic granulocyte colony-stimulating factor (G-CSF) therapy has been shown to reduce the incidence of SN and FN in patients receiving chemotherapy for non-myeloid malignancies and has been associated with increased chemotherapy relative dose intensity (RDI) compared with the absence of G-CSF support [4] [5] [6] [7] [8] [9] .
Retrospective analyses of randomized, controlled trials (RCTs) have shown an association between higher chemotherapy RDI and improved outcomes in patients receiving cytotoxic chemotherapy [10, 11] . A recent meta-analysis of RCTs assessing G-CSF primary prophylaxis in patients receiving myelosuppressive chemotherapy demonstrated a reduction in all-cause mortality among patients receiving G-CSF support [12] ; however, the effect of G-CSF primary prophylaxis on overall survival (OS) has not been well characterized in clinical trials. This retrospective analysis assessed the effect of G-CSF primary prophylaxis on OS in patients receiving myelosuppressive chemotherapy and filgrastim, pegfilgrastim, or placebo in five registrational RCTs for which outcome data were available [5] [6] [7] [8] [9] . methods studies and patients An overview of the five registrational RCTs is presented in Table 1 . The placebo-controlled trials were a phase 3 trial of filgrastim in small-cell lung cancer (SCLC) [5] , a phase 3 trial of pegfilgrastim in breast cancer (NCT00035594) [6] , and a phase 2 trial of pegfilgrastim in colorectal cancer (NCT00094809) [7] . Two phase 3 non-inferiority trials compared pegfilgrastim with filgrastim in breast cancer (referred to as non-inferiority study 1 [8] and non-inferiority study 2 [9] ).
Calculation of summary statistics for exposure to pegfilgrastim/filgrastim was based on the total dose for each patient over four cycles of chemotherapy ( pegfilgrastim dose = single dose × 4; filgrastim dose = single dose × days of dosing × 4). Similarly, the tabulation of the number of doses reflects the total number of doses received by a patient in four cycles. For patients who crossed over from placebo to G-CSF after cycle 1, summary statistics for exposure and the total number of doses were calculated based on a maximum of three cycles.
Meta-analysis of OS from the Cox proportional hazard (PH) models in the three placebo-controlled trials was carried out using a fixed-effect model; no measurable heterogeneity was detected (I 2 = 0%). Results of the metaanalysis at the level of individual patient data (IPD) with a stratified Cox PH model were identical.
data collection and analysis
The original publications of the placebo-controlled registrational trials reported OS/deaths for the intent-to-treat (ITT) analysis set. In this analysis, the treatment arms for OS/deaths were determined by the treatment actually received (as-treated set). Exposure to pegfilgrastim/filgrastim and OS are reported separately for patients who crossed over from placebo to G-CSF according to study design. The meta-analysis of the three placebo-controlled trials used the as-treated analysis sets.
incidence of severe neutropenia and febrile neutropenia Febrile neutropenia (FN) was defined as a temperature ≥38.2°C with ANC < 1.0 × 10 9 cells/l [5, 7] or ANC < 0.5 × 10 9 cells/l [6, 8, 9] on the same day [5] [6] [7] [8] [9] or the day after [6, 7] completion of chemotherapy. The incidence and duration of SN and FN were evaluated for the safety analysis set in the placebo-controlled studies. Differences between the G-CSF and placebo arms in the incidence of SN and FN were evaluated by calculating the relative risk (RR), where RR < 1.0 indicated a lower event rate for the G-CSF arm versus the placebo arm; P-values were calculated using the χ 2 test. The incidence of SN and FN was assessed only in cycle 1 because patients randomized to placebo in the lung and breast cancer studies who developed FN could cross over after cycle 1 to receive open-label filgrastim or pegfilgrastim, respectively [5, 6] . Blood collection for the assessment of ANC was carried out three days per week in the lung cancer study [5] , allowing reliable estimates of the duration of neutropenia. Because blood was collected only once per week in the breast and colorectal cancer studies [6, 7] , duration of neutropenia could not be assessed.
antibiotic use
Differences in intravenous and oral antibiotic use for any cause between the G-CSF and placebo arms were evaluated by calculating RR, where RR < 1.0 indicated a lower use rate for the G-CSF arm relative to the placebo arm; P-values were based on the χ 2 test. Deaths by extent of disease were summarized descriptively.
overall survival
The Kaplan-Meier estimates of OS (the time from study day 1 until death) and 6-and 12-month survival rates (where estimable) were compared between arms using an unadjusted log-rank test. Maximum follow-up time on the phase 3 breast cancer trial [6] was 159 days, insufficient to estimate 6-and 12-month survival. The median survival time was not reached for the two non-inferiority trials. Unadjusted Cox PH models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). A fixed-effect, study-level meta-analysis was carried out to estimate OS among the three placebo-controlled trials. In the absence of heterogeneity, the results from the IPD analysis (stratified on study) were identical. In the ITT analysis sets of the three placebo-controlled studies, the incidence of grade 3/4 neutropenia in cycle 1 was significantly lower among patients receiving G-CSF versus placebo ( Table 2 ). The incidences of grade 3/4 and grade 4 neutropenia were significantly lower among patients in the lung cancer study receiving filgrastim versus placebo (P = 0.0014 and 0.0001, respectively), as was the incidence of FN (P < 0.001). Likewise, the incidences of grade 3/4 and grade 4 neutropenia were significantly lower among patients in the breast cancer study receiving pegfilgrastim versus placebo (both P < 0.0001), as was the incidence of FN (P < 0.001). In the colorectal cancer study, the incidence of grade 3/4 neutropenia was significantly lower among patients receiving pegfilgrastim versus placebo (P = 0.0027).
cycle 1 antibiotic use
Oral and intravenous antibiotic use (any cause) in cycle 1 was significantly reduced among patients in the lung cancer study receiving filgrastim versus placebo (P = 0.0048) and among patients in the breast cancer study receiving pegfilgrastim versus placebo (P = 0.0007; Table 2 ). The difference in antibiotic use in the colorectal cancer study, however, was not statistically significant (P = 0.580).
exposure to G-CSF and chemotherapy
Across all studies, the median exposure (mg) to pegfilgrastim or filgrastim was similar (Table 3 ). In the two placebo-controlled trials, in which crossover from placebo to G-CSF was allowed by study design [5, 6] , the median exposure (mg and number of doses) was similar and consistent among patients receiving G-CSF for a total of four cycles beginning in cycle 1 and patients who crossed over from placebo and received G-CSF for a total of three cycles beginning in cycle 2. In the non-inferiority studies [8, 9] , the mean exposure was higher in pegfilgrastim treatment arms compared with filgrastim treatment arms. The studies included in this analysis reported limited information on chemotherapy RDI, with no information on dose reductions or delays reported in the placebo-controlled lung cancer study or the first non-inferiority breast cancer study [5, 9] . In the placebo-controlled trial in colorectal cancer [7] , a non-significant difference in the incidence of chemotherapy dose delays or reductions was observed between patients receiving pegfilgrastim versus placebo (33.4% versus 45%; P = 0.06). In the placebo-controlled trial in breast cancer [6] , 80% and 78% of patients in the pegfilgrastim and placebo groups, respectively, received their planned chemotherapy dose on time; these results were expected because patients who developed FN then crossed over to pegfilgrastim. The second non-inferiority breast cancer study reported similar chemotherapy dose administration between the filgrastim and pegfilgrastim arms, with 90% of patients receiving chemotherapy according to the planned schedule [8] .
overall survival and 6-and 12-month survival
There were generally fewer deaths among patients receiving G-CSF versus placebo in the placebo-controlled studies. There were also fewer OS events among patients receiving pegfilgrastim versus filgrastim in the non-inferiority studies (Table 4 ; Figure 1 ). In the lung cancer study, the point estimate for median OS was three months longer among patients receiving filgrastim only versus placebo only, but the difference was not statistically significant (P = 0.412 for HR). Among patients in the placebo arm receiving open-label filgrastim after cycle 1 as a result of FN, the point estimate for median OS was almost six months longer versus placebo only, but the difference was not statistically significant (P = 0.286 for HR). In the other studies, the median OS could not be estimated because of the small number of OS events. To evaluate the relationship between G-CSF primary prophylaxis and survival, a fixed-effect model meta-analysis of the placebo-controlled studies was carried out. In the as-treated analysis sets comparing G-CSF primary prophylaxis with placebo, the HR (95% CI) for OS was 0.77 (0.58-1.03).
In the placebo-controlled studies, where estimable, 6-and 12-month survival rates were generally higher among patients receiving G-CSF (beginning in cycle 1 or cycle 2) versus placebo (Table 4 ). In the non-inferiority studies, 6-and 12-month discussion Chemotherapy-induced FN can often result in chemotherapy dose delays or dose reductions, which may result in reduced chemotherapy RDI and compromised outcomes [13] [14] [15] [16] . Meta-analyses and pooled analyses have provided some evidence of an association between G-CSF primary prophylaxis and improved survival in patients receiving myelosuppressive chemotherapy [4, 12, 17] . In this retrospective analysis of RCTs of filgrastim and pegfilgrastim [5] [6] [7] , patients receiving G-CSF primary prophylaxis had greater median OS point estimates and greater 6-and 12-month survival rates versus placebo, but the benefits were not statistically significant. Similar non-significant increases in the median OS point estimate and 6-and 12-month survival rates were seen among patients with SCLC who were randomized to placebo but then crossed over to open-label filgrastim after experiencing FN during cycle 1. In the fixed-effect meta-analysis of the placebo-controlled studies (Cox PH model with no heterogeneity), the HR for OS was <1 in favor of G-CSF primary prophylaxis compared with placebo; although the result was not statistically significant, it may be considered hypothesis generating.
In contrast with the original reports of the registrational studies [5] [6] [7] [8] [9] , this analysis assessed OS data from patients in the as-treated analysis dataset rather than the ITT dataset to ensure that the OS estimate reflected the actual treatment received by patients. Results of our survival analysis are consistent with those in previous reports [4, 12, 17, 18] . In a meta-analysis of RCTs (n = 59), patients receiving G-CSF primary prophylaxis with myelosuppressive chemotherapy had reduced mortality risk versus patients without G-CSF support (RR, 0.93; P < 0.001) [12] . In an earlier meta-analysis of 17 RCTs, patients receiving primary prophylaxis with filgrastim, pegfilgrastim, or lenograstim had lower risk of infection-related mortality (RR, 0.55; P = 0.018) and early mortality during chemotherapy treatment (RR, 0.60; P = 0.002) versus patients without G-CSF support [4] . Evidence of improved survival has also been observed with G-CSF prophylaxis in patients receiving myelosuppressive chemotherapy for myeloid malignancies [17, 18] . Notably, a higher 5-year survival rate was observed with primary prophylaxis with filgrastim or lenograstim versus no prophylaxis in a subgroup of patients with acute lymphoblastic leukemia (44% versus 27%; P = 0.03) [17] . Additionally, patients receiving filgrastim or pegfilgrastim prophylaxis during the first cycle (P = 0.018) or any cycle (P = 0.04) of chemotherapy for acute myeloid leukemia survived longer than patients who did not receive prophylaxis [18] . Collectively, our retrospective analysis and these studies provide evidence that G-CSF primary prophylaxis may improve OS in patients receiving myelosuppressive chemotherapy.
In all three placebo-controlled studies, exposure to G-CSF was generally similar between active treatment arms, and the incidence of grade 3/4 neutropenia in cycle 1 was significantly lower among patients receiving G-CSF compared with those receiving placebo. The incidences of grade 4 neutropenia, FN, and antibiotic use in cycle 1 were also lower in the G-CSF arms of the placebo-controlled studies, but the differences were not statistically significant in the colorectal cancer study. The apparent treatment effect of G-CSF primary prophylaxis was likely reduced in the placebo-controlled SCLC [5] and breast cancer [6] studies, which allowed patients in the placebo arm to cross over to secondary prophylaxis with G-CSF after cycle 1 as a result of FN. This crossover design limited the ability to evaluate the impact of G-CSF on survival outcomes in these trials. This analysis had several limitations. First, the number of OS events was small, and the studies were neither designed nor powered to assess OS [5] [6] [7] [8] [9] . Secondly, patients who crossed over from the placebo arm to the G-CSF arm in cycle 2 did so after experiencing FN in cycle 1 and cannot be assumed to have the same risk of FN as patients who remained on the assigned therapy. In the lung cancer study, OS in the placebo-only arm may have been shortened by early deaths/withdrawals compared with the crossover arm in which patients survived to receive subsequent therapy. Thirdly, follow-up time was not equivalent among the studies (60-240 days in the placebo-controlled breast cancer study and non-inferiority study 1 versus 900-1000 days in the other studies). Fourthly, the studies differed in the tumor types and chemotherapy regimens and in how and when neutropenia was assessed. Lastly, because of limited availability of data, we were not able to determine in this analysis if patients receiving G-CSF experienced fewer chemotherapy dose delays or higher RDIs that may have correlated with improved outcomes. Despite these limitations, many of which were likely to bias against the G-CSFcontaining arm, point estimates for OS were greater among patients receiving G-CSF primary prophylaxis compared with placebo. However, the differences were not statistically significant.
Current guidelines recommend initiating primary prophylaxis with G-CSF in patients at high risk for FN in the first chemotherapy cycle or when needed for the on-time delivery of full-dose chemotherapy [19] [20] [21] [22] . Secondary prophylaxis is less desirable because many patients may experience neutropenic complications before receiving G-CSF support. Prospective assessment of the effects of G-CSF primary prophylaxis on long-term outcomes in patients with cancer receiving myelosuppressive chemotherapy is warranted.
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